122-0551(122-0551) - _专利_临床

概要

基本信息

药物类型

激素

别名

122-0551

靶点-

作用方式-

作用机制-

治疗领域

免疫系统疾病皮肤和肌肉骨骼疾病

在研适应症-

非在研适应症

斑块状银屑病

原研机构

Therapeutics, Inc.

在研机构-

非在研机构

Therapeutics, Inc.

权益机构-

最高研发阶段无进展临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

2

项与 122-0551 相关的临床试验

NCT01700985

/ Completed临床2期

A Double-Blind, Randomized, Single Center, Vehicle-Controlled, Parallel Group Study to Determine the Efficacy and Safety of 122-0551 in Subjects With Plaque Psoriasis Receiving Two Weeks of Treatment

Corticosteroids are one of the mainstays of treatment for subjects with corticosteroid-responsive dermatoses such as psoriasis. This study has been designed to determine and compare the efficacy and safety of a formulation of 122-0551 versus the corresponding Vehicle in subjects with stable plaque psoriasis after twice daily dosing for 14 consecutive days.

开始日期2012-05-01

申办/合作机构

Therapeutics, Inc.

NCT01698333

/ Completed临床2期

An Open Label Evaluation of the Adrenal Suppression Potential and Pharmacokinetic Properties of Twice Daily 122-0551 in Subjects With Plaque Psoriasis Receiving Two Weeks of Treatment

Adrenal suppression effects of corticosteroids are among the most important safety concerns for this group of products. This study is designed to determine the adrenal effects of the investigational formulation of 122-0551 and characterize the steady state pharmacokinetics of the formulation.

开始日期2012-04-01

申办/合作机构

Therapeutics, Inc.

100 项与 122-0551 相关的临床结果

登录后查看更多信息

100 项与 122-0551 相关的转化医学

登录后查看更多信息

100 项与 122-0551 相关的专利（医药）

登录后查看更多信息

100 项与 122-0551 相关的药物交易

登录后查看更多信息